- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02597881
Achondroplasia Natural History Multicenter Clinical Study
Registry of Patients With Bone Disorders
Study Overview
Status
Conditions
Detailed Description
The purpose of this protocol is to create an electronic registry to house phenotypic information from patients with all types of bone conditions. The initial focus of this registry will be to include U.S. patients with achondroplasia. Once populated by co-investigators with particular interest, expertise and large clinical populations with these bone conditions, the collective data can be queried to pursue clinical research questions pertaining to health outcomes and treatment options for patients with these complex conditions. The registry is longitudinal in nature with the functionality to retrospectively enter patients' clinical data from the prenatal period up through the most recent encounter, with all intervening data entered in a chronologic fashion. The database has been created in RedCap, a publicly available database format created by researchers at the University of Miami specifically for academic researchers collaborating across multiple research sites. The rationale for creating such a database is simple; achondroplasia is relatively rare so collaboration among researchers is essential to gather similarly affected patients to answer common clinical research questions. The goal is to better understand the natural history and treatment outcomes for these patients.
This registry was built by, based at and maintained by personnel from the Greenberg Center for Skeletal Dysplasias in the McKusick-Nathans Institute of Genetic Medicine (IGM) at Johns Hopkins. The registry is web-based and therefore easily accessible to our co-investigators at other sites across the U.S., including Alfred I. DuPont in Wilmington, Delaware, University of Wisconsin in Madison and University of Texas.
Our goal is to enroll at least 1500 patients with achondroplasia from the aforementioned sites. Access to the registry is password-protected and the data will be backed up on the IGM server daily. A co-investigator will be able to enter and access the identifying information (i.e. name, address, contact information, DOB) for their patients only in the registry. Thereafter, a unique study identification number, calculated age of the subject (based on the date of data entry) and diagnosis will be the only identifiers accessible to the other co-investigators. The total deidentified phenotype data will be available to the co-investigators during data analysis.
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Molecular or clinical diagnosis of achondroplasia (as confirmed by physical exam and/or radiograph review by the PI, one of the co-PIs or other qualified clinical geneticists)
- Subjects must have been seen for a clinical genetics visit at Johns Hopkins, Alfred I. DuPont Hospital for Children, University of Wisconsin-Madison or University of Texas
- Subjects may be active clinical patients at the above sites or no longer treated at a given site but with sufficient retrospective clinical data for extraction as determined by the PI or co-PIs
Exclusion Criteria:
- Skeletal dysplasia diagnosis other than heterozygous
- Achondroplasia
- There is no medical complication or condition which excludes a patient with achondroplasia
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection of growth measurements of patients with Achondroplasia using chart reviews
Time Frame: 3 years
|
Determine age at which linear growth ceases in patients with achondroplasia by gender
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of surgeries undertaken by achondroplasia patients using chart reviews.
Time Frame: 3 years
|
To quantify the total number, type, age indications and complications of all surgical interventions of a cohort of patients with achondroplasia
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Julie Hoover-Fong, MD,PhD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA_00086185
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achondroplasia
-
GeneScience Pharmaceuticals Co., Ltd.Tongji Hospital; Shengjing Hospital; Shandong Provincial Hospital; Children's Hospital... and other collaboratorsRecruiting
-
PfizerTerminatedAchondroplasiaBelgium, United States, Japan, Australia, Portugal, Denmark, Italy, Spain
-
PfizerTerminatedAchondroplasiaUnited States, Australia, Belgium, Denmark, Italy, Portugal, Spain
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Japan, United Kingdom
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaAustralia, United Kingdom
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, United Kingdom, Japan, Spain, Turkey
-
BioMarin PharmaceuticalPicnicHealthRecruitingAchondroplasiaUnited States
-
Ascendis Pharma Growth Disorders A/SActive, not recruitingAchondroplasiaUnited States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
-
Ascendis Pharma A/SActive, not recruitingAchondroplasiaUnited States, Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal
-
PfizerCompleted